Figure S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Published in 2023 by
Patrick Schöffski,
Rastislav Bahleda,
Andrew J. Wagner,
Melissa A. Burgess 
,
Niels Junker,
Michael Chisamore ,
Patrick Peterson,
Anna M. Szpurka,
Matteo Ceccarelli ,
William D. Tap
,
Niels Junker,
Michael Chisamore ,
Patrick Peterson,
Anna M. Szpurka,
Matteo Ceccarelli ,
William D. Tap
